HEALTH OF WOMAN. 2016.2(108):36–41; doi 10.15574/HW.2016.108.37 
 

Differentiated approach to the use of progesterone in obstetric and gynecologic practice 
 

Gopchuk E. N.

National Medical Academy of Postgraduate Education P. L. Shupyk, Kiev 
 

The use of combined treatment algorithm different dosage forms (sublingual and vaginal) managed to increase the therapeutic effect of micronized progesterone. The results related to the rapid action of sublingual and then supporting the action of the vaginal forms of Luteina formulation. Sublingual shape allows achieving a rapid effect, there is no primary hormone metabolism in the liver, and hence its concentration is not lost, and thus, this form of administration is the least long half-life. Due to reaching maximum concentrations within 30 minutes after sublingual administration and rapid effect in emergency situations, Luteina is an alternative preparation vaginal application of progesterone to maintain the required concentration. With the combination of sublingual and vaginal routes of administration increases the clinical effectiveness and safety of micronized progesterone in obstetric practice, so lutein drug can be recommended for widespread use.

Key words: Luteina, a sublingual form of micronized progesterone, a vaginal form of micronized progesterone, the threat of termination of pregnancy.

REFERENCES

1. Belyakov NA, Seyidov GB, Chubrieva SY, Glukhov NV. 2005. Metabolic syndrome in women (pathophysiology and clinic). StPb: 440.

2. Bitsadze VO, Akinshin SV, Hizroeva DH, Makatsaria NA, Stuleva NS, Mashkov TM. 2014. Pathogenetic rationale for the use of natural progesterone in ob tion practice. Obstetrics, Gynecology and reproduktsіya 2:79–88.

3. Boris EN, Kamіnsky AV. 2015. Porіvnyalne otsіnyuvannya efektivnostі zastosuvannya mіkronіzovanogo progesterone orally іntravagіnalno i sublіngvalno reproductive cycles dopomіzhnih tehnologіy i in the I trimestrі vagіtnostey. Women's health 3(99).

4. Bulavenko OV, Dzis NP, Furman OV. 2015. Treatment of endometrial hyperplasia in women of late reproductive age are overweight. Reproductive Health. Eastern Europe. 3(39).

5. Veropotvelyan PN, Veropotvelyan NP. 2015. Clinical approach to the correction of the luteal phase deficiency drug lutein. Reproductive Health 3.

6. Galich SR. 2014. Vpliv іntravagіnalnogo mіkronіzovanogo progesterone on platsentatsіyu, perebіg vagіtnostі that pologіv in zhіnok Yakimov boule zdіysnenі pregravіdarnі laparoskopіchnі operatsіy zovnіshnogo genіtalnogo endometrіozu. Health of Ukraine 2.

7. Golyanovsky OV, Rubіnshteyn AM, Bachinskaja MA. 2015. Efektivnіst kombіnovanogo zastosuvannya sublіngvalnoy that vagіnalnoy mіkronіzovanogo forms of progesterone in terapіy zagrozi peredchasnih pologіv. Women's health 8(104).

8. Іnstruktsіya for medichnogo zastosuvannya drug Luteіna.

9. Kaminsky VV, Zhuk SI. 2008. Tocolytic therapy: new features. Zhіnochy lіkar 6:3.

10. Makatsaria AD, Bitsadze VO. 2003. Thrombophilia and antithrombotic therapy in obstetric practice: 904.

11. Makatsaria AD, Beloborodov EV, Baymuradova SM, Bitsadze VO. 2005. Hyperhomocysteinemia and pregnancy complications: 147–180.

12. Malanchuk LM. 2010. The use of sublingual tablets of micronized progesterone in the treatment of endometrial hyperplastic processes. Women's Health 9(55).

13. Manukhin IB, Gevorgian MA et al. 1999. Metabolic disorders in women with polycystic ovary syndrome. Reproduction problems 4:7–13.

14. The order of Ministry of Health Ukraine from 31.12.2004 №676 «On approval of clinical protocols for obstetric and gynecological care» section «Premature birth» and changes to it №624 from 03.11.2008.

15. Nazarenko TA, Durinyan ER, Baibarina GV. Hyperandrogenism. 2004. A Practical Guide: 3–5.

16. Pirogov VI, Shurpyak SA. 2011. Gestagens with habitual miscarriage. Neonatologіya, hіrurgіya that perinatal medicine 1–2:154–158.

17. Reznikov AG. 2004. Progesterone drugs: pharmacological features, advantages, clinical application. Practicing doctor 3:5.

18. Skripchenko NY, Tuxa VG. 2014. Lіkuvannya nevinoshuvannya in vagіtnih s leyomіomoyu uterus іz zastosuvannyam natural progesterone mіkronіzovanogo. Women's Health 2(88).

19. Khomyak NV, Mazur VI. 2014. Clinical and Pharmacological features of modern formulations of micronized progesterone used during pregnancy. Women's Health 4(90).

20. Bulletti C, Cicinelli E, Ziegler DE et all. 2000. Direct transport of progesterone from vagina to uterus. Obstet Gynecol. 95:403–6. http://dx.doi.org/10.1097/00006250-200003000-00017; http://dx.doi.org/10.1016/S0029-7844(99)00542-6

21. Dodd JM, Flenady V, Cincotta R, Crowther CA. 2008. Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews.

22. Haas DM, Ramsey PS. 2008. Progestogen for preventing miscarriage. Cochrane Database Syst. Rev. 16(2):CD003511.

23. Pandian Ramachandhiran RMU, Adeeb N, Parampalam SD, Kathirkamanathan B, Ahmad Y, Thirunamam AE. 2009. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas.

24. Perricone C, de Carolis C, Perricone R. 2012. Pregnancy and autoimmunity: a common problem. Best Pract. Res. Clin. Rheumatol. 26(1):47–60.

25. Raghupathy R, Al Mutawa E, Makhseed M, Azizieh F, Szekeres–Bartho J. 2005. Modulation of cytokine production by dydrogesterone in lymphocytes from women with recurrent miscarriage. BJOG. 112(8):1096–1101.

26. Romero R, Nicolaides K, Conde–Agudelo A et al. 2012. Vaginal progesterone in women with an asymptomatic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and meta-analysis of individual patient data. Am. J Obstet. Gynecol. 206(2):124. e1–19

27. Lykjanchuk V.D. Kyznecova O.V. Doslidzenna in vitro rozchinnosti preparaty v tverdij dozovanij likarskij formi dla intravaginalnogo vvedenna. Medicinskie aspecti zdorovja zenshini 1 (97) 2016: 2-5.

28. Shantha S, Brooks–Gunn J, Locke RJ, Warren MP. 2001. Natural vaginal progesterone is associated with minimal psychological side effects: a preliminary study. J women′s Health Gender–based Med. 10:991–7. http://dx.doi.org/10.1089/152460901317193567; PMid:11788109

29. Thangaraju Shyam (IN). 2012. Randomized controlled study comparing the effectiveness of dydrogesterone and micronized progesterone in improving the sub–endometrial blood flow in idiopathic recurrent spontaneous miscarriage. Materials of the 15 th World Congress Gynecol. Endocrinol. Florence.